Clinical Trials Browser

Phase 2 × Unknown × Digestive System Diseases × Clear all

Digestive System Diseases, Thrombocytopenia

NCT05662813 2022-12-23

Almonertinib Therapy in Patients With Abnormal Liver Function After EGFR-TKI Treatment, or Almonertinib First-line Therapy in Patients With Basic Hepatopathy

Phase 2 Unknown

55 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Digestive System Diseases, Liver Diseases

NCT01037049 2018-09-17

Optimum Timing for Surgery After Pre-operative Radiotherapy 6 vs 12 Weeks

Phase 2 Unknown

237 enrolled

Gastrointestinal

Adenocarcinoma, Carcinoma, Adenocarcinoma, Mucinous, Digestive System Diseases, Digestive System Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Intestinal Diseases, Intestinal Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Rectal Diseases, Rectal Neoplasms, Colorectal Neoplasms, Neoplasms, Cystic, Mucinous, and Serous

NCT03011255 2017-08-07

Combination of Radiation Therapy and Peptide Specific CTL Therapy in Treating Patients With Esophageal Cancer

Phase 2 Unknown

20 enrolled

Gastrointestinal

Digestive System Diseases, Esophageal Diseases, Esophageal Neoplasms

NCT01247246 2014-05-26

Study to Evaluate the Efficacy and Safety of Three Different Doses of SCV 07 in Attenuating Oral Mucositis in Subjects With Head and Neck Cancer

Phase 2 Unknown

160 enrolled

GastrointestinalHead & NeckOther

Digestive System Diseases, Gastroenteritis, Gastrointestinal Diseases, Head and Neck Neoplasms, Stomatognathic Diseases, Mouth Diseases, Neoplasms, Neoplasms by Site, Stomatitis, Mucositis

Clinical Trials

Efficacy and Safety of Herombopag in Patients With Thrombocytopenia Before Hepatectomy

Almonertinib Therapy in Patients With Abnormal Liver Function After EGFR-TKI Treatment, or Almonertinib First-line Therapy in Patients With Basic Hepatopathy

Optimum Timing for Surgery After Pre-operative Radiotherapy 6 vs 12 Weeks

Combination of Radiation Therapy and Peptide Specific CTL Therapy in Treating Patients With Esophageal Cancer

Study to Evaluate the Efficacy and Safety of Three Different Doses of SCV 07 in Attenuating Oral Mucositis in Subjects With Head and Neck Cancer